Emerging nanotaxanes for cancer therapy
Yachao Zhang,Wenjing Zhang,Yongqi Wang,Jiaojiao Zhu,Mei Zhou,Can Peng,Zhonggui He,Jin Sun,Zhenbao Li,Shuangying Gui
DOI: https://doi.org/10.1016/j.biomaterials.2021.120790
IF: 14
2021-01-01
Biomaterials
Abstract:The clinical application of taxane (including paclitaxel, docetaxel, and cabazitaxel)-based formulations is significantly impeded by their off-target distribution, unsatisfactory release, and acquired resistance/metastasis. Recent decades have witnessed a dramatic progress in the development of high-efficiency, low-toxicity nanotaxanes via the use of novel biomaterials and nanoparticulate drug delivery systems (nano-DDSs). Thus, in this review, the achievements of nanotaxanes?targeted delivery and stimuli-responsive nano-DDSs?in preclinical or clinical trials have been outlined. Then, emerging nanotherapeutics against tumor resistance and metastasis have been overviewed, with a particular emphasis on synergistic therapy strategies (e.g., combination with surgery, chemotherapy, radiotherapy, biotherapy, immunotherapy, gas therapy, phototherapy, and multitherapy). Finally, the latest oral nanotaxanes have been briefly discussed.